KRAS and non-small cell lung carcinoma: Mutations in genes such as BRAF, KRAS, and human epidermal growth factor receptor 2 (HER2) also play crucial roles in subtyping NSCLC, with emerging targeted therapies tailored to these specific mutations (23) (Figure 1).